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OBJECTIVES The purpose of this study was to investigate the incidence, morphology, and clinical course
of thrombus formation after catheter closure of intra-atrial shunts.
BACKGROUND Post-procedure detailed information about thrombotic material on different devices for
transcatheter closure is missing.
METHODS A total of 1,000 consecutive patients were investigated after patent foramen ovale (PFO) (n
 593) or atrial septal defect (ASD) (n  407) closure. Transesophageal echocardiography
(TEE) was scheduled after four weeks and six months. Additional TEEs were performed as
clinically indicated.
RESULTS Thrombus formation in the left atrium (n  11), right atrium (n  6), or both (n  3) was
found in 5 of the 407 (1.2%) ASD patients and in 15 of the 593 (2.5%) PFO patients (p 
NS). The thrombus was diagnosed in 14 of 20 patients after four weeks and in 6 of 20 patients
later on. The incidence was: 7.1% in the CardioSEAL device (NMT Medical, Boston,
Massachusetts); 5.7% in the StarFLEX device (NMT Medical); 6.6% in the PFO-Star device
(Applied Biometrics Inc., Burnsville, Minnesota); 3.6% in the ASDOS device (Dr. Ing,
Osypka Corp., Grenzach-Wyhlen, Germany); 0.8% in the Helex device (W.L. Gore and
Associates, Flagstaff, Arizona); and 0% in the Amplatzer device (AGA Medical Corp.,
Golden Valley, Minnesota). The difference between the Amplatzer device on one hand and
the CardioSEAL device, the StarFLEX device, and the PFO-Star device on the other hand
was significant (p 0.05). A pre-thrombotic disorder as a possible cause of the thrombus was
found in two PFO patients. Post-procedure atrial fibrillation (n  4) and persistent atrial
septal aneurysm (n  4) had been found as significant predictors for thrombus formation (p
 0.05). In 17 of the 20 patients, the thrombus resolved under anticoagulation therapy with
heparin or warfarin. In three patients, the thrombus was removed surgically.
CONCLUSIONS The incidence of thrombus formation on closure devices is low. The thrombus usually resolves
under anticoagulation therapy. (J Am Coll Cardiol 2004;43:302–9) © 2004 by the
American College of Cardiology Foundation
Transcatheter closure of atrial septal defect (ASD) and
patent foramen ovale (PFO) has become a less invasive
alternative to open heart surgery. The first attempt at
transcatheter closure of an ASD was described by King and
Mills in 1974 (1,2). Since then, there has been a remarkable
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evolution of devices with different materials, mechanism of
closure, and methods of implantation (3–19). Although
excellent results have been reported for transcatheter occlu-
sion with different devices (3–19), concerns have arisen
about peri- and/or post-interventional complications
(5,20,21). Information about thrombus formation on de-
vices and its clinical outcome is very limited (21–23). The
purpose of our study was to determine and analyze the
incidence, morphology, possible predictors, and clinical
management of thrombus formation on ASD and PFO
closure devices in 1,000 consecutive patients.
METHODS
Patient population. Between August 1992 and January
2003, transcatheter closure of a PFO (n  593) or an ASD
(n 407) was performed in 1,000 consecutive patients (579
females and 421 males) between the age 13 and 90 years
(mean age 48  15 years). Nine different devices were used:
1) Rashkind (USCI Bard, Billerica, Massachusetts); 2)
Buttoned (Custom Medical Devices, Amarillo, Texas); 3)
ASDOS (Dr. Ing, Osypka Corp., Grenzach-Wyhlen, Ger-
many); 4) Angel Wings (Das Angel Wings, Microvena
Corp., Vadnais, Minnesota); 5 and 6) CardioSEAL and
StarFLEX (NMT Medical, Boston, Massachusetts); 7)
Amplatzer (AGA Medical Corp., Golden Valley, Minne-
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sota); 8) Helex (W. L. Gore and Associates, Flagstaff,
Arizona); and 9) PFO-Star (Applied Biometrics Inc.,
Burnsville, Minnesota).
The stretched ASD diameter, measured with a balloon
catheter, varied between 6 and 37 mm (mean 20  6 mm)
and pulmonary/systemic output ratio from 0.4 to 4.7 (mean
2.0  0.7). Of the ASD patients, 50 (12%) had multiple
defects. In 15 (30%) of these 50 patients, two devices were
implanted. An atrial septal aneurysm (ASA) defined as an
excursion of the septum of more than 10 mm was present in
52 (13%) of the ASD patients. The following concomitant
diseases were present in the ASD patients: pulmonary
hypertension in 133 (33%) patients, atrial fibrillation (AF)
in 56 (14%), coronary artery disease in 34 (8%) patients,
systemic hypertension in 88 (22%) patients, diabetes in 17
(4%) patients, phlebothrombosis in 18 (4%) patients, and
embolic events (stroke, transient ischemic attack [TIA], and
peripheral embolism) in 65 (16%) patients.
In the PFO patients, an ASA was present in 157 (27%)
cases. The stretched diameter of the PFO was also defined
by balloon sizing and ranged from 4 to 21 mm (mean 9 
3 mm). In these patients, 741 embolic events occurred
before PFO closure: 353 strokes, 315 TIAs, 38 prolonged
reversible ischemic neurologic deficits, and 35 peripheral
embolisms with no other known source. On average, the
patients had 1.2 embolic events before the procedure. The
annual recurrence rate after the first event was 25%.
Some ASD and PFO patients had coagulation disorders,
such as protein C deficiency (ASD: n  2; PFO: n  7;
p  NS), protein S deficiency (ASD: n  3, PFO: n  5;
p  NS), or activated protein C resistance (ASD: n  9;
PFO: n  16; p  NS). Overall, 14 of 221 (6.3%) ASD
patients and 28 of 235 (12%) PFO patients had one of these
disorders. This difference was not significant. Of the pa-
tients with an ASD, 65 had an embolic event before defect
closure. In total, 300 patients had an embolic event (235
PFOs and 65 ASDs). In these 300 patients a coagulation
disorder was diagnosed in 39 (13%) cases compared with
only 3 (19%) cases in those 156 patients without an embolic
event (p  0.001).
Abbreviations and Acronyms
AF  atrial fibrillation
ASA  atrial septal aneurysm
ASD  atrial septal defect
PFO  patent foramen ovale
TEE  transesophageal
echocardiographic/echocardiography
TIA  transient ischemic attack
TTE  transthoracic echocardiographic/echocardiography
Table 1. Comparative Summary of Percutaneous ASD and PFO Occlusion Devices
Device Design and Construction
Rashkind-PDA-Umbrella Double umbrella (2nd generation Rashkind occluder) made of polyurethane
foam, each disc consists of a 4-arm framework.
Device sizes: 11 and 17 mm
Buttoned Device (3rd and
4th generation)
1) square occluder button; 2) rhomboid counter occluder.
Device sizes: 25 to 50 mm
ASDOS Two self-opening umbrellas (5-arm nitinol wire skeleton) with polyurethane
membranes.
Device sizes: 25 to 60 mm
Angel Wings Two interconnected square (each 4 legs) nitinol wire frames covered with
Dacron (polyester) fabric with a central conjoint ring.
Device sizes: 18 to 40 mm
CardioSEAL Non-centering double umbrella device modified from the Clamshell device
with a 4-arm metallic framework covered with Dacron.
Device sizes: 17 to 40 mm
StarFLEX Double umbrella device developed from the CardioSEAL device with a 4-
or 6-arm metallic framework, Dacron fabric, self-centering mechanism
achieved by nitinol microsprings.
Device sizes: 23 to 40 mm
Amplatzer Self-centering double disc with a short connecting waist made from nitinol
wire frame filled with polyester fabric.
Device sizes (ASD): 4 to 40 mm; device sizes (PFO): 25 to 35 mm
Helex Single length of nitinol wire with ultrathin expanded polytetrafluoroethylene
which is formed into two equal-size opposing discs that bridge the septal
defect.
Device sizes: 15 to 35 mm
PFO-Star (1st and
2nd generation)
Two Ivalon-square discs, each umbrella is expanded by 4 nitinol arms—1st
generation: 2-mm center posts; 2nd generation: 3- and 5-mm center
posts.
Device sizes: 18 to 30 mm
ASD  atrial septal defect; PFO  patent foramen ovale.
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Closure devices. Table 1 provides an overview of the
devices used in this series. These have been described in
detail elsewhere (3–19).
Occlusion procedure. The procedures were performed
under local anesthesia unless the patient did not tolerate the
transesophageal echocardiographic (TEE) probe. Detailed
echocardiographic assessment of the size and morphology of
the ASD or PFO and the correct positioning of the device
was performed using a multiplane 5-MHz probe. Pa-
tients were fully heparinized (10,000 to 20,000 U hepa-
rin), and antibiotic prophylaxis was given. Measurements
of the defect and occlusion techniques with the different
devices have been reported previously (3–19). Until
October 2001 (in 817 patients) heparin was antagonized
with protamine at the end of the procedure. Therefore,
the patients were usually discharged on the same or
following day.
Follow-up. A clinical examination, an electrocardiograph,
a chest radiograph in two projections, and a transthoracic
echocardiograph (TTE) were performed before discharge
and repeated after 1, 6, and 12 months. In addition, TEE
follow-up has been performed according to different study
protocols approved by the local institutional review board.
The TEE was scheduled four weeks and six months after
closure with the newer devices: StarFLEX, Amplatzer,
Helex, and PFO-Star. In older device protocols (Cardio-
SEAL, Angel Wings, ASDOS, Buttoned Device, and
Rashkind), control TEE after four weeks was optional, and
at six months it was recommended. Cardiac catheterization
was performed in patients with moderate and large residual
shunts. Fluoroscopy to evaluate the metallic structures of the
device was also performed after six months. Thereafter,
follow-up was performed by a questionnaire every 6 to 12
months. In the event of a recurrent embolic situation,
additional clinical investigations were performed as neces-
sary. In event of a thrombus, repeat TEEs were scheduled
until resolution of the thrombus.
Anticoagulation therapy. According to different device
protocols, different regimens of anticoagulation and anti-
platelet therapy were begun after implantation. Anticoagu-
lation with warfarin (target international normalized ratio 2
to 3 for patients with the Rashkind and ASDOS devices) or
anti-aggregation with aspirin (100 mg daily for patients
with the Buttoned, Angel Wings, CardioSEAL, Star-
FLEX, Amplatzer, and Helex devices) was conducted for
six months. As for the PFO-Star study protocol, clopidogrel
(75 mg daily) was additionally recommended for three
months. Since January 2001 (in 264 patients), protocols
were changed for all PFO patients to a combination of
aspirin and clopidogrel for six months.
Statistical analysis. Data were described as mean  SD,
and percentages were expressed where appropriate. Com-
parisons of results in patients with and without thrombus
formation and between different devices were assessed by
chi-square test; this was replaced by the Fisher exact test in
cases in which the cell frequency was 5. A multiple
regression analysis was performed to determine how vari-
ables (predisposing factors) were related to the risk of
thrombus formation on ASD and PFO closure devices after
implantation. A value of p  0.05 was considered to be
statistically significant.
RESULTS
Implantation of the device was technically successful in all
patients. However, two attempts were necessary in 13
patients. During a follow-up period of 1 to 108 months
(mean 36  17 months; 1,327 patient-years), a thrombus
formation was detected in 20 of 1,000 (2%) patients.
Thrombus formation in the left atrium (n  11), right
atrium (n  6), or both (n  3) was found in 5 of the 407
(1.2%) ASD patients and in 15 of the 593 (2.5%) PFO
patients (p  NS). The TEE had been performed four
weeks after closure in 709 of 1,000 (71%) patients and after
six months in 714 of 1,000 (71%) patients. Thrombotic
structures were observed by TEE after four weeks in 14
patients (Table 2), after six months in 3 patients (Table 2),
after one year in 2 patients, and after five years in 1 patient.
None of these thrombi could be detected by TTE, which
had also been performed in all patients at the same time.
The diameter of the thrombi varied from 5 to 30 mm (mean
11.7  7 mm). The thrombus appeared as pedunculated
Table 2. Thrombus Formation at 4-Week TEE and 6-Month TEE After Closure
Occluder n
TEE Due (n) TEE Performed (%) Thrombus (%, n)
6 Months 4 Weeks 6 Months 4 Weeks 6 Months
Rashkind 1 1 100% 100% 0% 0%
Buttoned Device 52 52 67% 69% 0% 0%
ASDOS 42 42 66% 83% 3.6% (n  1) 0%
Angel Wings 30 30 0% 97% 0% 3.3% (n  1)
CardioSEAL 27 27 52% 93% 7.1% (n  1)* 0%
StarFLEX 142 111 74% 70% 5.7% (n  6)* 0%
Amplatzer 418 375 78% 70% 0%* 0.3% (n  1)
PFO-Star 127 127 60% 66% 6.6% (n  5)* 1.5% (n  1)
Helex 161 138 76% 80% 0.8% (n  1) 0%
*The difference between the Amplatzer occluder against the CardioSEAL occluder, the StarFLEX occluder, and the PFO-Star
occluder was significant (p  0.05).
TEE  transesophageal echocardiography.
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and mobile in 9 (45%) cases (Fig. 1A). Immobile thrombi
were detected in 11 (55%) patients (Fig. 1B). In two of these
patients, a right atrial thrombus was attached to the lateral
atrial wall (Fig. 1C) without direct contact to the occlusion
device.
In devices with star-shaped metallic arms (CardioSEAL,
StarFLEX, and PFO-Star occluder; n  14) thrombus
formations seemed to be attached either at the center of the
right or left atrial disc (n 5), at the transitional epithelium
between device and septum (n  1), or attached to the
expanded nitinol or metal arms (n  8).
Four weeks after implantation, the TEE revealed a
thrombus formation in 14 of 709 (2%) patients, with an
incidence of 0% to 7.1% for different devices (Table 2). The
difference between the Amplatzer (0%) versus the Cardio-
SEAL (7.1%), the StarFLEX (5.7%), and the PFO-Star
(6.6%) was significant (p  0.05, Fisher exact test) (Table
2). The Amplatzer had the lowest incidence of thrombi
against each of those devices. Post-procedure AF (n  4;
p  0.05) and persistent ASA (n  4; p  0.01) were
significant predictors for thrombus formation determined by
the Fisher exact test. These and other possible risk factors
for thrombus formation are summarized in Table 3. Pre-
thrombotic disorders were found in two PFO patients
(thrombocytosis in one patient and hyperactivity of factor
VIII in one patient). Two minor strokes caused by a
left-sided mobile thrombus on a StarFLEX device (one of
these patients had a hyperactivity of factor VIII). One minor
stroke (patient with a thrombocytosis) and one TIA oc-
curred in two PFO-Star patients. No other pre-thrombotic
disorders were found in these 20 thrombi patients. Of the
20 patients, 17 had a good outcome with disappearance of
the thrombus following anticoagulation therapy with hep-
arin (n  1), warfarin (n  12), or both (n  4). Repetitive
TEE examinations showed that the thrombotic material on
the device was completely resolved in 11 of 20 cases after
one month and in 6 of 20 cases after a time period of
between two and six months. In three patients the thrombus
was removed surgically:
Patient 1: A left-sided mobile thrombus on a StarFLEX
device was removed together with the device after
cerebral embolism and unsuccessful fibrinolysis.
Patient 2: A large right-sided thrombus (30  18 mm)
attached to the lateral atrial wall did not disappear
under long-term warfarin treatment and was removed
surgically. The ASDOS occluder was left in place.
Only a tip of wire sticking out of the covered device
had been cut (Fig. 2).
Patient 3: In this asymptomatic patient diagnosed with
AF and four small mobile left-sided thrombi seen on
TEE on the StarFLEX occluder, the referring phy-
sician decided to send the patient to surgery. During
surgery, the left-sided thrombus could not be found
anymore, but an 8-mm right-sided thrombus not
diagnosed before was detected and removed together
with the device (Fig. 3).
DISCUSSION
Atrial thrombi after transcatheter ASD and PFO closure are
rare complications (20,24,25). We investigated the inci-
dence of thrombus formation on nine different devices in
1,000 consecutive patients to determine possible predictors.
A thrombus formation was found in 5 of the 407 (1.2%)
ASD patients and in 15 of the 593 (2.5%) PFO patients
(p  NS). La Rosee et al. (23) described thrombus
formation in 3 of the 38 (10.5%) ASD patients and in 8 of
Figure 1. (A) Transesophageal echocardiography four-chamber view: left-
sided mobile thrombus attached to a StarFLEX occluder detected four
weeks after catheter closure. (B) Transesophageal echocardiography short-
axis: right- and left-sided immobile thrombus surrounding an ASDOS
occluder detected four weeks after catheter closure. (C) Transesophageal
echocardiography short-axis: large mobile thrombus (30  18 mm)
attached to the right atrial wall (without direct contact to the ASDOS
device) detected one year after catheter closure. LA  left atrium; RA 
right atrium.
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the 60 (13.3%) PFO patients (p  NS). These were
diagnosed early, two to three days after implantation. The
investigators found a thrombotic structure in 7 of the 40
(17.5%) patients on the ASDOS occluder, in 3 of the 33
(9%) patients on the PFO-Star occluder, and in 1 of the 25
(4%) patients on the Amplatzer occluder (p  NS). In
contrast to La Rosee et al. (23), we found atrial thrombi
after four weeks only in 1 of the 28 (3.6%) ASDOS devices,
5 of the 76 (6.6%) PFO-Star devices, and 0 of the 328 (0%)
Amplatzer devices. Other previous reports revealed a
thrombus incidence of 6.5% (9 of 139) in the ASDOS
device (17) and 11.1% (3 of 27) in the Buttoned device (26).
According to the data of nine different devices implanted in
our center, we verified that thrombus formation is not only
a clinical event of older devices; newer devices also demon-
strate the potential to develop early thrombus formation
after four weeks: 1 of 14 (7.1%) CardioSEAL, 6 of 105
(5.7%) StarFLEX, 5 of 76 (6.6%) PFO-Star (1st and 2nd
generation), and 1 of 123 (0.8%) Helex.
Furthermore, we found that the difference between the
Amplatzer device (0%) on one hand and the CardioSEAL
device (7.1%), the StarFLEX device (5.7%), and the PFO-
Star device (6.6%) on the other hand was significant (p 
0.05). The Amplatzer nitinol wire frame filled with polyes-
ter fabric and the Helex nitinol wire covered by an ultra thin
membrane of expanded polytetrafluoroethylene seem to be
less thrombogenic than the metallic framework and Dacron
fabric in the CardioSEAL and StarFLEX devices and the
nitinol framework and Ivalon foam in the PFO-Star oc-
cluder. Uncoated metal arms in the CardioSEAL and
StarFLEX devices and outside nitinol arms in the PFO-Star
devices (1st and 2nd generation) may increase the risk for
excessive thrombus formation. This has also been affirmed
by Braun et al. (19). In their largest PFO-Star device study,
adherent thrombus formations could only be detected in
generations 1 and 2 when expanded nitinol arms were
located on the outer side of the foam. In the 3rd generation,
the PFO-Star device nitinol arms were placed from the
outer to the inner side of the left atrial foam. After these
changes, no further thrombi were noted by TEE.
Possible predictors of thrombi. After the procedure we
found paroxysmal AF and persistent ASA to be significant
predictors for thrombus formation (Table 3). The preva-
lence of AF and persistent ASA was higher among patients
with thrombus formation than in those without (AF: 20%
vs. 6.2%, p  0.05; ASA: 20% vs. 1.3% p  0.001).
Table 3. Potential Risk Factors for Thrombus Formation
Risk Factors After
Defect Closure
Patients Without
Thrombi
Patients With
Thrombi p Value
Atrial fibrillation 66/980 (6.2%) 4/20 (20%)  0.05
Residual shunt immediately after closure 287/980 (29%) 3/20 (15%) NS
Persistent atrial septal aneurysm 13/980 (1.3%) 4/20 (20%)  0.01
Wire fracture 47/980 (4.8%) 3/20 (15%) NS
Protein S deficiency 8/456 (1.8%) 0/20 (0%) NS
Protein C deficiency 9/456 (2%) 0/20 (0%) NS
Resistance to activated protein C 25/456 (5.5%) 0/20 (0%) NS
Mean age 47 yrs 48 yrs NS
Gender
Male 412/980 (42%) 9/20 (45%) NS
Female 568/980 (58%) 11/20 (55%) NS
Hypertension 228/980 (23%) 3/20 (15%) NS
Coronary artery disease 51/980 (5%) 0/20 (0%) NS
Diabetes 37/980 (4%) 0/20 (0%) NS
Warfarin 95/980 (10%) 3/20 (15%) NS
Aspirin 505/980 (52%) 6/20 (30%) NS
Aspirin  clopidogrel 380/980 (39%) 11/20 (55%) NS
Protamin 798/980 (81%) 19/20 (95%) NS
Figure 2. Unsuccessful resolution of a large right-sided thrombus (30  18 mm) attached to the lateral atrial wall under long-term warfarin treatment.
During surgery the ASDOS occluder was left in place. Only a tip of wire sticking out of the covered device had been cut.
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However, this has to be addressed carefully because of the small
number of thrombus formations (n  20) detected in our
study. Moreover, there is some evidence that patients with
ASA benefit from occlusion in reducing the mobility of the
septum. In a previous study (27), the septal excursion had been
significantly reduced in 48 of 51 patients six months after
closure. A persistent ASA could be found in only 3 of 51
patients. None of them developed an atrial thrombus post-
procedure. In our thrombus patients with persistent ASA, no
recurrent thromboembolic events occurred. Windecker et al.
(28) affirmed that after transcatheter closure the presence of
ASA and PFO does not result in a higher recurrence rate of
cerebrovascular events; thus, this group of patients would
particularly benefit from closure.
No other significant predictors for thrombus formation
on several devices could be found. A post-procedural shunt
was detected in 3 of the 20 (15%) thrombus patients. A wire
device frame fracture was also observed in 3 of 20 (15%)
patients: 1 ASDOS, 1 CardioSEAL, and 1 PFO-Star
occluder. In all three patients the side of the wire fracture
was consistent with the side of the atrial thrombus. These
patients all had right-sided atrial thrombi attached to
right-sided broken arms or frames. In a study with the
Buttoned device, Lambert et al. (26) noted that tilting the
occluder created a large residual defect and was associated
with left atrial thrombosis. Of the 27 Buttoned devices
displaced in that way, 3 (11%) developed thrombus forma-
tion. Coagulation disorders such as protein C deficiency,
protein S deficiency, and activated protein C resistance did
not exist in our thrombus cases; only a hyperactivity of factor
VIII and a thrombocytosis could be found in two patients.
Gastmann et al. (24) reported a case of a left-sided throm-
bus formation on an ASDOS device resulting in cerebral
thromboembolism. This patient had a deficiency of coagu-
lation factor XII.
Other risk factors for cardiovascular disease, such as
diabetes, coronary artery disease, and hypertension may not
conduct thrombus formation on implanted devices. Among
patients with (n  20) and without (n  980) thrombus
formation, no significant differences could be determined in
terms of age or gender. According to different study
protocols, ASD and PFO patients received different medical
prophylaxes after catheter closure either with antiplatelet
agents or with anticoagulants (warfarin: n  98, aspirin: n
 511, aspirin  clopidogrel: n  391). Our results do not
favor any medical regimen. Patients without thrombi (n 
980) were treated with warfarin in 10% of cases (n  95),
with aspirin in 52% of cases (n 505), and with aspirin and
clopidogrel in 39% of cases (n 380), compared to patients
with thrombi (n  20), who received warfarin in 15% of
cases (n  3), aspirin in 30% of cases (n  6), and aspirin
 clopidogrel in 55% of cases (n  11). However, these
differences were not significant.
There are no additional studies comparing these three
therapeutic regimes relating to the incidence of thrombi
formations on devices. In a PFO-Star device study of 276
patients, Braun et al. (19) found that ever since change in
the antiplatelet therapy from aspirin alone to a combination
of aspirin and clopidogrel, no further thrombotic material
occurred. Unfortunately, no statistical evaluation comparing
both therapeutic regimes concerning the incidence of
device-adherent thrombus was made.
In a smaller Amplatzer device study by Brandt et al. (29),
37 patients (ASD: n  21; PFO: n  16) received
clopidogrel and aspirin after transcatheter closure for six
months. In an absence of any thrombus at four weeks’ and
six months’ TEE, the investigators concluded that this
antiplatelet therapy is safe and effective in preventing
thrombus formation on the septal occluder surface. How-
ever, they did not have a control group who received aspirin
alone. In our study, uncertainty remains regarding the
combination of aspirin  clopidogrel because there seemed
to be no significant benefit in this particular thrombotic
prophylaxis. Of 391 patients with this treatment, 11 (2.8%)
developed thrombi after transcatheter closure compared to
the patient group, who received only aspirin and detected
thrombi in 6 of 511 (1.2%) patients (p  NS). It has to be
mentioned that heparin was antagonized with protamine
immediately after the procedure in 267 of 391 (68%)
patients and 10 of 11 (91%) thrombus cases who received
aspirin and clopidogrel. Anti-heparin therapy with prota-
mine in the first hours after implantation might be a
disadvantage and thus enhance thrombogenesis. Therefore,
we stopped antagonizing heparin in November 2001. Since
Figure 3. A short transesophageal view of small mobile left-sided thrombi on a StarFLEX occluder. During surgery, the absence of the left-sided thrombi
but detection of a right-sided thrombus (8 mm) not diagnosed before was removed together with the device. AO  aorta; LA  left atrium; RA  right
atrium.
307JACC Vol. 43, No. 2, 2004 Krumsdorf et al.
January 21, 2004:302–9 Thrombus Formation on Intracardiac Devices
then only one thrombus occurred in 183 patients. In all 183
patients a four-week TEE had been performed. However,
this has not yet been statistically significant.
In general, resolution of thrombi had been achieved
under medical treatment in 17 of 20 patients within four
weeks to six months; 12 patients received warfarin, 1 patient
received heparin, and 4 patients received a combination of
heparin and warfarin. In 11 of 17 patients, the thrombus
disappeared after four weeks. Therefore, we currently rec-
ommend initial anticoagulation therapy for three months,
similar to other studies (19,20) with repetitive TEE exam-
inations depending upon diameter and mobility of device-
attached thrombi.
Complications related to thrombus formations. Cardiac
surgery was performed in only three patients. One left-sided
and one right-sided mobile thrombus attached to a Star-
FLEX occluder in two patients was removed together with
the device, after cerebral embolism and unsuccessful fibri-
nolysis in one and as decided by the referring physician in
the other. In the third patient a large right-sided throm-
bus—not device-related—attached to the lateral atrial wall
did not disappear under long-term warfarin treatment. This
thrombus was removed surgically, leaving the ASDOS
occluder in place. No further thrombi or other complica-
tions occurred in these three patients.
During follow-up, 4 of 20 (20%) patients became symp-
tomatic and suffered from thromboembolic events. Two
minor strokes occurred in patients with a StarFLEX oc-
cluder, and one minor stroke and one TIA occurred in two
PFO-Star device patients. There have been other reports
about left-sided thrombus formation on ASDOS (24,25)
and Buttoned (26) devices complicated by systemic embo-
lism. In the ASDOS device case, reported by Gastmann et
al. (24), the patient had a deficiency of coagulation factor
XII that is known to be associated with thrombotic com-
plications. The large left-sided thrombus completely re-
solved after one month. In two of our four thrombus cases
resulting in acute strokes, coagulation disorders were also
found (hyperactivity of factor VIII in a patient with an ASD
occluded with a StarFLEX and thrombocytosis in a patient
with a PFO-Star occluder). All patients fully recovered from
these neurological deficits.
If some patients endangered by thromboembolic compli-
cations nevertheless undergo transcatheter closure, antico-
agulation monitoring requires exceptional attention. Similar
to other investigators (20,24), we state that TTE is usually
unable to detect thrombus formation on the device. Accord-
ing to our results we recommend that all adult patients,
including those with good echocardiographic windows,
should have a routine TEE examination after 4 weeks, 6
months, and 12 months. For younger children, follow-up by
TTE as an imaging perspective might be sufficient. To shed
light on the performed follow-up studies of these 1,000
consecutive patients, a group of them did not return for one
of the TEE examinations at four weeks (n 291) and at six
months (n  286), factors relating either to different device
protocols or to personal declining. These patients were
checked by interviews, clinical examination, electrocardiog-
raphy, chest X-ray, and TTE at 1, 6, and 12 months
following implantation. None of them suffered from a TIA
or a stroke.
Thrombus formation and cerebrovascular events after
surgical defect closure. There is still an ongoing discussion
(30,31) about the gold standard for the best therapeutic
approach (catheter closure, medical therapy, or even sur-
gery) in ASD and PFO patients. Surgical closure has also
been attempted with mixed results in terms of recurrent
embolic events derived by thrombus formation. Most re-
cently, Rodriguez et al. (32) noted an intra-atrial thrombus
with a small residual PFO six months after surgical PFO
closure. Homma et al. (33) reported in a series of 28
patients, four recurrent neurological events (one stroke and
three TIAs) after surgical closure at a mean follow-up of 19
months. In these particular patients (two were treated with
aspirin and two received no medical treatment), no intra-
cardiac mass or thrombus was seen by TEE, and only a
small residual shunt was found in two cases. The recurrence
only occurred in the older population (45 years). Thus, the
investigators concluded there must be some undefined
causes for their patients’ strokes.
In a larger study, Dearani et al. (34) documented eight
TIAs during a mean follow-up of two years following
surgical closure, one caused by temporal arteritis. Using
TEE they also demonstrated that all closures had been
intact without thrombotic structures. Having multiple em-
bolic events before PFO closure was the only significant risk
factor for recurrence after closure.
In a different study, Konstantinides et al. (35) found AF
in six of nine patients who suffered from a recurrent stroke
or TIA after surgical ASD closure. Only two of the six
patients with AF received anticoagulants at the time of the
event, that occurred in the late postoperative phase (30
days after surgery). Reviewing additional surgical closure
data it has to be mentioned that there are surgical studies
(36,37) with excellent results and no report of neurological
recurrences following patients who were embolic free up to
an average of 24 and 41 months. However, prospective and
randomized clinical trials are warranted to compare percu-
taneous closure directly with other treatment strategies such
as medical therapy and surgical repair of intra-atrial shunts.
Conclusions. The incidence of thrombus on closure de-
vices is low. We found significant differences between
different devices. Atrial fibrillation and persistent ASA after
transcatheter closure are significant risk factors for thrombus
formation. In most of the patients the thrombus resolved
under medical therapy without clinical consequences.
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